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To the Editor:
Santana-Davila et al1 have 
recently reported in this Journal a ret-
rospective study on data from Veterans 
Health Administration Central Cancer 
Registry aiming to compare the efficacy 
and toxicity of cisplatin- to carboplatin-
based doublet chemotherapy in 4352 
metastatic non–small-cell lung can-
cer (NSCLC) patients treated between 
2001 and 2008.1
Overall, the authors report that 
the use of cisplatin-based doublets was 
not associated with a better survival 
than that of carboplatin-based ones 
(8.1 versus 7.5 months; adjusted analy-
sis, hazard ratio: 0.98, 95% confidence 
interval: 0.84–1.14). No differences 
were also showed in subgroup analy-
sis according to histology and second 
agent. Cisplatin-treated patients were 
more likely to have hospitalization 
and outpatient visits, more subsequent 
encounters for infection and acute 
kidney injury/dehydration. Therefore, 
the authors conclude that this “study 
supports the use of carboplatin as one 
agent of doublet chemotherapy for all 
patients with advanced NSCLC”. In 
our opinion, however, this conclusion is 
weakened by several study limitations, 
as properly commented by the authors 
themselves.
Carboplatin versus cisplatin-
based doublet comparison was per-
formed in this analysis between 4061 
versus 291 patients, respectively, and, 
in particular, 3992 versus 193 patients, 
treated with third-generation regimens. 
Therefore, the number of cisplatin-
treated patients was very low respect 
to 1489 and 1169 patients considered 
in the individual data CISplatin vs 
CArboplatin (CISCA) meta-analysis 
overall and treated with third-gener-
ation combinations, respectively.2 In 
this meta-analysis, cisplatin-based che-
motherapy resulted slightly superior to 
carboplatin-based treatment in terms 
of response rate and, in non-squamous 
tumors and with third-generation regi-
mens, also in survival prolungation.
A second limitation concerns 
toxicity. In the CISCA meta-analysis, 
cisplatin-based chemotherapy was 
associated with more severe nausea/
vomiting and nephrotoxicity, similarly 
to the Santana-Davila et al; whereas no 
differences were revealed in neutrope-
nia, as reported in this study. The com-
bination of cisplatin with etoposide and 
docetaxel in more than 50% of patients 
(versus < 10% in carboplatin-based 
treatment) could partially justify this 
worst potentially life-threatening toxic-
ity, which might have counterbalanced 
a small survival benefit associated with 
cisplatin.
Thirdly, even if methodologi-
cal study flaws have been extensively 
addressed by the authors, nevertheless 
the absence of PS information and the 
high percentage of not otherwise speci-
fied histology (in particular in cisplatin-
group, 42.6%) should deserve special 
consideration. The high percentage of 
not otherwise specified, known as an 
independent poor prognostic factor, 
could be related to a high percentage 
of cytological diagnosis, more frequent 
in elderly and/or in patients with poor 
clinical conditions.3
Finally, the survival data reported 
in this study are inferior to those seen 
in recent clinical trials with more active 
cisplatin-based combination, such as 
cisplatin pemetrexed.4 Therefore, the 
results of this study are hardly applica-
ble to the current standard of care (only 
4.5% of patients received cisplatin-
pemetrexed) which is mainly based, at 
least in Europe, on cisplatin pemetrexed.
In summary, the analysis of 
Veterans is very interesting, but the 
results are pertinent mainly to a com-
munity setting NSCLC population and 
could not be generalized at all advanced 
NSCLC patients. For selected fit and 
not elderly patients without significant 
comorbidities, most of the available 
scientific evidence, in our opinion, still 
supports the use of last generation cis-
platin-based regimens.
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